DHVC United States

Life Science and Healthcare Venture Capital Investor
Website:
www.dh.vc
Company Size (Fulltime employees)
Year of foundation
2013
Partnering Objectives
Please specify your partnering goal
Investment
Headquartner in China
Medtech Development Stage
Ali Farahanchi
Managing Director 
Functionality

GIG China

GIG, one of the leading healthcare investment institute, was founded in Shenzhen in 2001. AUM is RMB ¥20b. It has invested in 80+ healthcare companies. 22 went IPO. GIG has 90+ staff in team with operating offices in Shenzhen, Shanghai, Beijing, Nanjing and Hongkong.

Website:
www.szgig.com
Company Size (Fulltime employees)
Please specify your partnering goal
potential investing targets and collaborations
Headquartner in China
Medtech Development Stage
Denise Chen
Partner 
Functionality

Maryland Department of Commerce United States

Our team at the Maryland Department of Commerce assists companies to establish operations and partnerships in one of the leading ecosystems for the life science industry in the United States.
- As one of the nation’s largest and fastest growing biotechnology clusters, Maryland is #1 in Ph.D. concentration in biological fields, employed doctoral scientists, and was recognized last year at the 4th best biotechnology cluster in the nation by Genetic Engineering and Biotechnology News.
- We have facilitated access to 74 Federal laboratories, including the National Institutes of Health, the National Institute for Standards and Technology, the Food and Drug Administration, and the Walter Reed Army Institute of Research.
- We can reach 80% of the U.S. pharmaceutical industry and four nearby international airports to enable efficient travel.
- Maryland’s Cost of Doing Business Index is 16%, 12%, and 10% lower than in Boston, New Jersey, and California, respectively, according to Moody’s Analytics Regional Financial Review. In our industry, that translates to a lower cost of operations and wet lab space.
- The cost of living in Maryland can be up to one-and-a-half times lower than in the metropolitan areas of New York, Boston, and San Francisco, according to the Council for Community and Economic Research.
Company Size (Fulltime employees)
Year of foundation
1632
Partnering Objectives
Please specify your partnering goal
We are seeking companies that would like to establish operations in the United States or in-license US technology to China.
Headquartner in China
Medtech Development Stage
Felicia Pullam
Regional Manager, Asia 
Functionality

Regulaxis France

Regulaxis SAS is a French biotech company created in 2013 to develop innovative therapies for human clinic based on new synthetic peptides regulating cell growth and differentiation.

Regulaxis is specialized in the regulation of cell proliferation and/or cell differentiation. The potential therapeutic applications covered by our patents are very broad, especially in the areas of joint/bone or nerve cell regeneration, but also in cancer and related metabolic diseases (diabetes, obesity …).
Our mission is to grant licenses of innovative molecules in a pharmaceutical company after completion of phase II clinical proof of concept.

Regulaxis is strategically focused only on high unmet medical needs but has elected as its first priority:
regeneration of articular cartilage using intra-articular injections of its lead candidate REG-O3.

Company Size (Fulltime employees)
Year of foundation
2013
Please specify your partnering goal
Fundraising
Headquartner in China
Biotech/Pharma Category
Assets Information 1
CN109862905A published 2019-06-07 | Methods for treating osteoarthritis by administering linked variants of growth hormone and somatostatin | The present invention relates to the treatment of osteoarthritis. In particular, the present invention relates to peptides for use in the treatment of osteoarthritis
Biotech/Pharma Asset Stage
Medtech Information 1
Diagnostic companion kit OsteoArthritis
Medtech Development Stage
Slides Deck
(png, 430.99KB)
Dr. Matthieu CHAREYRE
Dr. Matthieu CHAREYRE
LinkedIn logo Chief Business Development Officer - Global Pharmaceutical Operations 
Functionality

SYNERGYMED DEVICES INC. United States

We develop a medical device that treats cancer tumors as an alternative to surgery
Company Size (Fulltime employees)
Year of foundation
2018
Partnering Objectives
Please specify your partnering goal
To Perform Clinical Trials together in order to launch the product in China
Headquartner in China
Biotech/Pharma Category
Medtech Category
Medtech Information 1
||R&D|
Medtech Development Stage
Slides Deck
(pdf, 2.67MB)
Anan Copty
Founder & CEO 
Functionality